Microbix & BioGX Collaborate on real-time PCR Assays & Controls

By Microbix Admin | December 7, 2023

Microbix Announces Initiation of Normal Course Issuer Bid

By Microbix Admin | December 6, 2023

Microbix Presenting at Florida Capital Event Conference

By Microbix Admin | November 17, 2023

Microbix Clot-Buster Drug Fully-Funded For Return to U.S. Market

By Microbix Admin | November 16, 2023

Microbix & Ulisse Biomed Collaborate on HPV Controls & Assays

By Microbix Admin | November 10, 2023

Microbix QAPs Supporting HPV Testing in Ireland

By Microbix Admin | October 27, 2023

Episode 3: Diagnostics: Beyond the lab – Self-Collection with Copan Italia

By Microbix Admin | October 21, 2023

Episode 5: Diagnostics Beyond the Lab: Bridging Policy and innovation for a healthier tomorrow

By Microbix Admin | October 20, 2023

Microbix Presenting at Muskoka Capital Conference

By Microbix Admin | September 29, 2023

Microbix Achieves New QAPs Sales Record

By Microbix Admin | September 27, 2023

Microbix Honours the Passing of its Founder William J. Gastle – 1948 to 2023

By Microbix Admin | September 13, 2023

Microbix Reports Results for Q3 Fiscal 2023

By Microbix Admin | August 10, 2023

Microbix Successfully Upgrades Logistics Software Systems

By Microbix Admin | August 7, 2023

Microbix Presents Results of STI Test Controls at AACC

By Microbix Admin | July 24, 2023

Microbix QAPs Supporting HPV Testing Across The Netherlands

By Microbix Admin | July 5, 2023

Respiratory virus multiplex formulations desiccated on Copan’s FLOQSwab© for use as cross-platform compatible EQA samples – and laboratory Quality Control

By Microbix Admin | June 20, 2023

Microbix & Labquality Create Novel Testing Accreditation Program

By Microbix Admin | June 20, 2023

Evaluating the performance of STI POC assays using Swab format Quality Controls

By Microbix Admin | June 18, 2023

Performance of NAAT that detect MGEN using Swab Quality Controls

By Microbix Admin | June 18, 2023

Microbix Secures Funded Drug Commercialization Agreement

By Microbix Admin | May 16, 2023

Microbix Reports Results for Q2 Fiscal 2023

By Microbix Admin | May 11, 2023

Episode 4: Diagnostics Beyond the Lab: Ensuring Patient Health through EQA

By Microbix Admin | April 24, 2023

Diagnostics Explained: AMR

By Microbix Admin | February 21, 2023

CEM Muskoka – September 23-25

By Microbix Admin | February 8, 2023

Upcoming Events 2023

By Microbix Admin | February 2, 2023

Upcoming Events: Coming Soon

By Microbix Admin | January 27, 2023

Blog: Episode 3

By Microbix Admin | January 13, 2023

Blog: Episode 2

By Microbix Admin | January 10, 2023

Blog: Episode 1

By Microbix Admin | January 5, 2023

2022 Q2 Financial Report

By Microbix Admin | November 11, 2022

High-Risk HPV Quality Controls are Needed to Uphold Clinical Laboratory Quality Standards

By Microbix Admin | November 10, 2022

Emerging requirements for infectious disease IVD quality control material

By Microbix Admin | November 10, 2022

Expected stability of REDx&#8482FLOQ © SARS-CoV-2 Swab Positive Control and REDx&#8482FLOQ© SARS-CoV-2 Swab Negative Control in various sample transport media and storage conditions

By Microbix Admin | November 9, 2022

2022 Q3 Financial Report

By Microbix Admin | November 9, 2022

Use of REDx™FLOQ © SARS-CoV-2 Ag Swab Positive Control and REDx™FLOQ© Respiratory Swab Negative Control as Quality Control by POC devices in various testing conditions

By Microbix Admin | November 8, 2022

Novel Cross-Platform High-Risk (hr) HPV NAAT Positive Controls for Use in L1 and E6/E7 Targeted Nucleic ACID (DNA and RNA) Detection Methods

By Microbix Admin | November 8, 2022

Cross-Platform High-Risk (hr) Low Occurrence HPV NAAT Positive Samples of Use in Nucleic Acid Detection Testing as Prospective External Quality Assessment Samples – and User Defined Quality Controls

By Microbix Admin | November 8, 2022

Performance of full and extended genotyping assays using a new high-risk HPV multiplex panel

By Microbix Admin | November 7, 2022

Respiratory virus multiplex formulations desiccated on Copan’s FLOQSwab® for use as cross-platform compatible EQA samples and laboratory Quality Control

By Microbix Admin | November 6, 2022

Novel Mycoplasma genitalium (Mgen) and AMR Mgen A2059G Materials for use in a Cross-Platform NAAT Quality Control

By Microbix Admin | November 6, 2022

Simulated swab specimens for whole workflow quality control of SARS-CoV-2 molecular diagnostic testing

By Microbix Admin | November 5, 2022

2022 Q1 Financial Report

By Microbix Admin | November 5, 2022

Advanced SARS-CoV-2 Variants of Concern (VOC) whole-genome materials for use as verification, external quality assessment (EQA) and prospective quality control samples

By Microbix Admin | November 4, 2022

Episode 2: Diagnostics: Beyond the Lab – AMR MGEN with Colin Denver from SpeeDx

By Microbix Admin | November 4, 2022

Advanced SARS-CoV-2 nucleocapsid protein swab-based formulation for use as a cross-platform EQA sample and as a prospective Quality Control

By Microbix Admin | November 3, 2022

Novel neutralizing anti-S1 SARS-CoV-2 human monoclonal antibody formulation for use as a cross-platform EQA sample and prospective quality controls

By Microbix Admin | November 2, 2022

Novel SARS-CoV-2 Full-Genome Material for Use in a Swab-Based Formulation as a Multi-Platform NAAT Quality Control

By Microbix Admin | November 1, 2022

Episode 1: Diagnostics: Beyond the lab – HPV with Larry Vaughn, BD and Dr. Cathy Popadiuk

By Microbix Admin | November 1, 2022

MBX Investor Update Webinar

By Microbix Admin | October 31, 2022

AGM Presentation – March 2022

By Microbix Admin | October 31, 2022

AGM PRESENTATION 2022

By Microbix Admin | October 31, 2022

Microbix Corporate Presentation – September 2022

By Microbix Admin | October 31, 2022

Microbix Corporate Presentation – October 2022

By Microbix Admin | October 31, 2022

Novel Cross-Platform High-Risk (hr) HPV NAAT Positive Controls for Use in L1 and E6 / E7 Targeted Nucleic ACID (DNA and RNA) Detection Methods

By Microbix Admin | October 24, 2022

Cross-Platform High-Risk (hr) Low Occurrence HPV NAAT Positive Samples of Use in Nucleic Acid Detection Testing as Prospective External Quality Assessment Samples and User Defined Quality Control

By Microbix Admin | October 24, 2022

Emerging requirements for infectious disease IVD quality control materials

By Microbix Admin | October 18, 2022

CEM Florida – November 11-13

By Microbix Admin | July 25, 2022

About us

By Microbix Admin | June 22, 2022

2022 AMMI Canada-CACMID Annual Conference – April 5-8

By Microbix Admin | March 3, 2022

2022 EUROGIN International Multidisciplinary HPV Congress – April 10-13

By Microbix Admin | March 3, 2022

Why We Need To Test COVID-19 Tests

By Microbix Admin | March 3, 2021

Microbix Discloses New Products, Sales, And Capacity

By Microbix Admin | October 29, 2020 Microbix Discloses New Products, Sales, And Capacity

Microbix Creates Further COVID-19 Quality Assessment Products

By Microbix Admin | October 20, 2020 Microbix Creates Further COVID-19 Quality Assessment Products

Ontario Helps Microbix Ensure Provincial COVID Testing Capacity

By Microbix Admin | October 13, 2020 Ontario Helps Microbix Ensure Provincial COVID Testing Capacity

Microbix Presenting COVID-19 Product Results To Industry

By Microbix Admin | September 22, 2020 Microbix Presenting COVID-19 Product Results To Industry

Microbix Announces Extension Of Warrant Expiry Dates

By Microbix Admin | September 17, 2020 Microbix Announces Quality Products Distribution Agreement

Microbix Announces Board Changes

By Microbix Admin | September 15, 2020 Microbix Announces Board Changes

Microbix’s REDx™ Controls Attain Australian TGA Registration

By Microbix Admin | September 10, 2020 Microbix’s REDx™ Controls Attain Australian TGA Registration

Q3 Fiscal 2020

By Microbix Admin | August 14, 2020

Curious To See How We Perform A COVID Test?

By Microbix Admin | July 21, 2020 Microbix

Microbix Shares Become Available For U.S. Investors

By Microbix Admin | July 14, 2020 Microbix Shares Become Available For U.S. Investors

Microbix COVID-19 QAPs Attain EU “CE Mark” Registration

By Microbix Admin | June 5, 2020 Microbix COVID-19 QAPs Attain EU “CE Mark” Registration

Microbix Announces Quality Products Distribution Agreement – Appointment of Medical Supply Company of Ireland

By Microbix Admin | June 4, 2020 Microbix Announces Quality Products Distribution Agreement

Microbix Engaged To Develop & Supply Custom QAPs™

By Microbix Admin | June 2, 2020 Microbix Engaged To Develop & Supply Custom QAPs™

Microbix Expanding QAPs™ Production Capacity

By Microbix Admin | May 27, 2020 Microbix Expanding QAPs™ Production Capacity

Microbix Achieves Full Utilization Of Its Bioreactors

By Microbix Admin | May 19, 2020 Microbix Achieves Full Utilization Of Its Bioreactors

Microbix Announces Quality Products Distribution Agreement – Appointment of Labquality Oy of Finland for 7 Countries

By Microbix Admin | May 15, 2020 Microbix Announces Quality Products Distribution Agreement

Microbix Reports Record Second Quarter Sales – Year-Over-Year Sales Growth of 28% in First-Half

By Microbix Admin | May 14, 2020

Microbix Reports Results For Q2 Fiscal 2020

By Microbix Admin | May 14, 2020 Microbix Shares Become Available For U.S. Investors

Microbix Announces Quality Products Distribution Agreement – Appointment of D.I.D. S.p.A. of Milan for Italy

By Microbix Admin | May 12, 2020 Microbix Announces Quality Products Distribution Agreement

Microbix COVID-19 QAPs Now Available for U.S. Labs

By Microbix Admin | May 7, 2020

Microbix Begins Providing COVID-19 Test Quality Products

By Microbix Admin | May 6, 2020 Microbix Begins Providing COVID-19 Test Quality Products

Microbix Announces Quality Products Distribution Agreement – Appointment of R-Biopharm AG for 11 Countries

By Microbix Admin | April 27, 2020 Microbix Announces Quality Products Distribution Agreement

Microbix Participating In COVID-19 Virtual Conference

By Microbix Admin | April 21, 2020 Microbix Participating In COVID-19 Virtual Conference

Microbix Attains Health Canada Establishment Licensing

By Microbix Admin | April 21, 2020 Microbix Attains Health Canada Establishment Licensing

How Microbix Core Competency Leads To COVID-19 Products

By Microbix Admin | April 14, 2020 Microbix

Understanding COVID-19 Mortality Rates

By Microbix Admin | April 13, 2020

Microbix & Oneworld Create COVID-19 Test Quality Program

By Microbix Admin | April 9, 2020 Microbix Attains Health Canada Establishment Licensing

Microbix Announces Annual And Special Meeting Voting Results – April 2, 2018

By Microbix Admin | April 1, 2020

Microbix Creates Quality Assessment Product For COVID-19 Tests

By Microbix Admin | March 30, 2020

Microbix Annual General Meeting Process Update

By Microbix Admin | March 25, 2020

Microbix Announces Quality Products Distribution Agreement – Appointment of Alpha-Tec Systems, Inc. for the United States

By Microbix Admin | March 24, 2020

Microbix Announces Issuance Of Stock Options – Sep 13th 2017

By Microbix Admin | February 25, 2020 Microbix Announces Addition to Board of Directors

Microbix Reports Results For Q1 Fiscal 2020

By Microbix Admin | February 13, 2020

Annual General Meeting (AGM) – March 31st, 2020 UPDATE!

By Microbix Admin | February 3, 2020

Microbix Completes Non-Brokered Private Placement Of $2.3 Million

By Microbix Admin | January 31, 2020

Microbix Reports Results For Fiscal 2019

By Microbix Admin | December 20, 2019 Microbix Shares Become Available For U.S. Investors

EUROGIN 2019

By Microbix Admin | December 4, 2019

Microbix Invited To Present Product Results At HPV Congress

By Microbix Admin | December 2, 2019

Microbix Wins Ontario Business Award

By Microbix Admin | November 18, 2019 Microbix Announces Addition to Board of Directors